Impact of Prophylactic Antivirus Therapy on Outcomes of Kidney Transplantation in Hepatitis B Virus Carriers.
G. Chen,J. Qiu,C. Wang,X. Lai,J. Li,G. Huang,J. Fei,S. Deng,Q. Fu,L. Chen
DOI: https://doi.org/10.1097/00007890-201407151-02615
2014-01-01
Transplantation
Abstract:Background The efficacy of prophylactic antivirus therapy on Hepatitis B virus (HBV) carriers in kidney transplantation is still controversial. We carried out a retrospective case-control study to evaluate the impact of prophylactic antivirus therapy on long-term outcomes of HBV carriers after kidney transplantation. Methods We retrospectively reviewed HBV carriers with HBsAg-positive before kidney transplantation performed in our hospital from January, 2001 to December, 2010. All recipients were HBV-DNA negative before transplantation. 137 HBV carriers received prophylactic antivirus therapy after kidney transplantation, and these patients were matched by 137 HBV carriers who did not receive antivirus therapy based on HBeAg status and age. The patients were followed up, and HBV-DNA was detected every 3 months or when serum aminotransferases were abnormal. The primary endpoints were HBV reactivation (HBV-DNA transferring to positive), graft loss or patient death. Hepatic dysfunction, hepatic failure and hepatocellular carcinoma were also recorded. Kaplan-Meier analysis was used to evaluate the impact of prophylactic therapy on graft and patient survival. Results 137 patients received prophylactic antivirus therapy (96 received lamivudine, 41 received entecavir). Patients received prophylactic antivirus therapy could significantly reduce HBV reactivation rate after kidney transplantation (17.5% vs. 28.5%, p=0.031). In patients with HBeAg-positive, HBV reactivation rate was 5/20(25%) in prophylactic group versus 12/20(60%) in non-prophylactic group (p=0.025). Prophylactic antivirus therapy could also reduce the incidences of hepatic dysfunction (35% vs. 47.4%, p=0.037) and hepatic failure (0.7% vs. 5.8%, p=0.036). Hepatocellular carcinoma rate was comparable between two groups (2.2% vs. 3.6%, p=0.722). Kaplan-Meier analysis showed that prophylactic antivirus therapy could significantly improve 1-, 5-, and 10-year patient survivals (97.1%, 92.7%, and 86.6% vs. 94.2%, 83.9% and 76.4% respectively, p=0.047). However, 1-, 5-, and 10-year graft survivals were comparable between two groups (91.2%, 79.6%, and 62.2% vs. 90.2%, 77.2% and 58.2% respectively, p=0.462). Conclusion Prophylactic antivirus therapy may reduce HBV reactivation, hepatic dysfunction and hepatic failure in HBV carriers after kidney transplantation, and improve long-term patient survival.